Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Real World Study Evaluating the Persistence and Adherence of Subcutaneously Administered Biologics in Patients with Psoriatic Arthritis seen in Routine Clinical Practice

Trial Profile

A Real World Study Evaluating the Persistence and Adherence of Subcutaneously Administered Biologics in Patients with Psoriatic Arthritis seen in Routine Clinical Practice

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2018

At a glance

  • Drugs Adalimumab (Primary) ; Certolizumab pegol (Primary) ; Etanercept (Primary) ; Golimumab (Primary) ; Secukinumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Sponsors Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 16 Jun 2018 Results (n=1558) assessing the persistence of subcutaneously (SC) administered biologics in patients with psoriatic arthritis over 12 months of follow-up, presented at the 19th Annual Congress of the European League Against Rheumatism.
    • 23 May 2018 Results (n=1558) presented at the 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
    • 12 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top